Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.
Conditions studied
Colorectal Cancer, Breast Cancer
About this study
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.
Interventions
- Drug: Capecitabine-based chemotherapy — Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
Primary outcomes
- Occurrence of gastrointestinal toxicity (Six months)
- Occurrence of hand-foot syndrome (Six months)
Eligibility information
Study locations
- Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibīn al Kawm, Menoufia 32511 Egypt
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-17.